MariaI.CancioMD

Pediatric Hematology & Oncology • New York, NY

Associate Professor

Overview of Dr. Cancio

Dr. Maria Cancio is a pediatric hematologist/oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center and New York-Presbyterian Hospital. She received her medical degree from University College of Dublin National Univ SOM and has been in practice 14 years. She is one of 95 doctors at Memorial Sloan Kettering Cancer Center and one of 135 doctors at New York-Presbyterian Hospital who specialize in Pediatric Hematology & Oncology. She also speaks multiple languages, including Spanish. She has more than 20 publications and over 500 citings.

Office
1275 York Avenue
New York, NY 10065
Book by Phone+1(862) 972-4278

Education & Training

University of TennesseeFellowship, Pediatric Hematology/Oncology, 2011 - 2014
Johns Hopkins UniversityResidency, Pediatrics, 2007 - 2010
University College of Dublin National Univ SOMClass of 2006, Summa cum laude, Honours
Memorial Sloan Kettering Cancer CenterPost-Doctoral Fellowship, BMT

Certifications & Licensure

FL State Medical License 2021 - Present
NY State Medical License 2015 - 2026
NC State Medical License 2020 - 2022
TN State Medical License 2014 - 2015
MD State Medical License 2010 - 2010
American Board of Pediatrics Pediatrics
American Board of Pediatrics Pediatric Hematology-Oncology

Clinical Trials

TCR Alpha Beta T-cell and CD19 B-cell Depleted Peripheral Blood Stem Cell Transplantation Using the CliniMACS System for Patients With Non-Malignant Hematologic Disorders From Matched or Mismatched, Related or Unrelated Donors Start of enrollment: 2018 Jul 23
Terminated
Phase 2
Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders Start of enrollment: 2020 Nov 20
Recruiting
Phase 2
A Dose Escalation Study of FP-045 in Patients With Fanconi Anemia Start of enrollment: 2023 Jun 30
Recruiting
Phase 1, Phase 2
Roles: Contact
A Dose Escalation Study of FP-045 in Patients With Fanconi Anemia Start of enrollment: 2023 Jun 30
Recruiting
Phase 1, Phase 2
Roles: Contact
A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT) Start of enrollment: 2023 Feb 09
Recruiting
Phase 2
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Persistent or New Cytopenias Predict Relapse Better than Routine Bone Marrow Aspirate Evaluations After Hematopoietic Cell Transplantation for Acute Leukemia or Myelod...
Nancy A Kernan, Elizabeth Klein, Audrey Mauguen, Joanne Torok-Castanza, Susan E Prockop
Transplantation and Cellular Therapy. 2024-07-01
Retrospective Evaluation of Cystatin C as a Measure of Renal Function in Pediatric Hematopoietic Stem Cell Transplant Patients Receiving Foscarnet for Cytomegalovirus ...
Logan R Pickett, Nicole P Daukshus, Christine Camacho-Bydume, Sherry Mathew, Audrey Mauguen
The Pediatric Infectious Disease Journal. 2024-05-01
Two novel assays demonstrate persistent daratumumab exposure in a pediatric patient with delayed engraftment following allogeneic hematopoietic stem cell transplantation.
Hannah Major-Monfried, Kinga Hosszu, Devin P McAvoy, Alexander Vallone, Neerav Shukla
Cytotherapy. 2024-05-01

Abstracts/Posters

Allogeneic CD34-Selected HSCT Following CAR T-Cells Is Associated with Low TRM and Favorable OS in Pediatric/Young Adult Patients with Relapsed/Refractory B-ALL
Maria I. Cancio, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Other Languages

Spanish